SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. Chem Pharmacol Bull 1972; 24: 63243.
  • 2
    Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticon-vulsant drug. Pharmacological profile. Arzneimittelforsch 1980; 30: 47783.
  • 3
    Ito T, Hori M, Masuda Y, Yoshida K, Shimizu M. 3-Sulfamoyl-methyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile. Arzneimittelforsch 1980; 30: 6039.
  • 4
    Wada Y, Hasegawa H, Okuda H, Yamaguchi N. Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev 1990; 12: 20610.
  • 5
    Hori M, Ito T, Yoshida K, Shimizu M. Effect of anticonvulsants on spiking activity induced by cortical freezing in cats. Epilepsia 1979; 20: 2536.
  • 6
    Ito T, Hori M, Yoshida K, Shimizu M. Effect of anticonvulsants on experimental cortical epilepsy induced by tungstic acid gel in rats. Arch Int Pharmacodyn 1979; 241: 28799.
  • 7
    Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia 1986; 27: 36774.
  • 8
    Fromm GH, Shibuya T, Terrence CF. Effect of zonisamide (CI-912) on a synaptic system model. Epilepsia 1987; 28: 6739.
  • 9
    Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs. In: LevyRH, MattsonRH, MeldrumBS. eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995; 1011.
  • 10
    Suzuki S, Kawakami K, Nishimura S. et al Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 217.
  • 11
    Ito T, Yamaguchi T, Miyazaki H. et al Pharmacokinetic studies of Ad-810, a new antiepileptic compound, phase I trials. Arzneimittelforsch 1982; 32: 15816.
  • 12
    Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto M. Absorption, distribution and excretion of 3-(sulfamoyl[14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in man. Arzneimittelforsch 1983; 33: 9618.
  • 13
    Juergens U. Simultaneous determination of zonisamide and nine other antiepileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography. J Chromatogr 1987; 385: 23340.
  • 14
    Furuno K, Oishi R, Gomita Y, Eto K. Simple and sensitive assay of zonisamide in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J Chromatogr [B] 1994; 656: 4569.
  • 15
    Kaibe K, Nishimura S, Ishii H, Sunahara N, Naruto S, Kuraoka S. Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibod. Clin Chem 1990; 36: 247.
  • 16
    Buchanan RA, Bockbrader HN, Chang T, Sedman AJ. Single- and multiple-dose pharmacokinetics of zonisamide [Abstract]. Epilepsia 1996; 37(suppl 5):172.
  • 17
    Taylor CP, McLean JR, Bockbraer HN. et al Zonisamide (AD-810, CI-912). In: MeldrumBS, PorterRJ. eds. New anticonvulsant drugs. London : John Libbey, 1986: 27794.
  • 18
    Page JG, Kochak GM, Polvino WJ, Buchanan RA. Multiple dose zonisamide metabolism [Abstract]. Epilepsia 37(suppl 5):172.
  • 19
    Mimaki T, Tanoue H, Matsunaga Y, Miyazaki H, Mino M. Regional distribution of [14C]zonisamide in rat brain. Epilepsy Res 1994; 17: 2236.
  • 20
    Stiff DD, Zemaitis MA. Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dis 1990; 18: 88894.
  • 21
    Sugihara K, Kitamura S, Tatsumi K. Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Disp 1996; 24: 199202.
  • 22
    Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 1992; 22: 111.
  • 23
    Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kitada M. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Disp 1993; 21: 77781.
  • 24
    Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 1993; 44: 21621.
  • 25
    Nakasa H, Ohmori S, Kitada M. Formation of 2-sulphamoylacetyl-phenol from zonisamide under aerobic conditions in rat liver microsomes. Xenobiotica 1996; 26: 495501.
  • 26
    Nakasa H, Komiya M, Ohmori S, Kitada M, Rikihisa T, Kanakubo Y. Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes. Res Commun Chem Pathol Pharmacol 1992; 77: 3141.
  • 27
    Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. Pharmacokinetic interaction of zonisamide in rats: effect of other antiepileptics on zonisamide. J Pharmacobiol Dyn 1992; 15: 6319.
  • 28
    Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T. The necessity of adjusting the dosage of zonisamide when coad-ministered with other anti-epileptic drugs. Biol Pharmacol Bull 1996; 19: 10902.
  • 29
    Ojemann LM, Shastri RA, Wilensky AJ. et al Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8: 2936.
  • 30
    Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Asved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 20611.
  • 31
    McJilton J, DeToledo J, DeCerce J, Huda S, Abubakr A, Ramsay RE. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels [Abstract]. Epilepsia 1996; 37(suppl 5):173.
  • 32
    Wagner JG, Sackellares JC, Donofrio PD, Berent S, Sakmer E. Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984; 6: 27783.
  • 33
    Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharmacol Bull 1994; 17: 3236.
  • 34
    Matsumoto K, Miyazaki H, Fujii T, Miyazaki H, Hashimoto M. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction. Chem Pharmacol Bull 1989; 37: 280710.
  • 35
    Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics. Biol Pharmacol Bull 1993; 16: 7225.
  • 36
    Kaneko S, Hayashimoto A, Niwayama H, Fukushima Y. Effects of zonisamide on serum levels of phenytoin and carbamazepine. Jpn J Epilepsy Soc 1993; 11: 315. (in Japanese).
  • 37
    Tasaki K, Minami T, Ieiri I. et al Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995; 17: 1825.
  • 38
    Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia 1985; 26: 21220.
  • 39
    Wilder BJ, Ramsay RE, Guterman A. et al A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of Dainippon Pharmaceutical Co., Ltd., 1986.
  • 40
    Schmidt D, Jacob R, Loiseau P. et al Zonisamide for add-on treatment of refractory partial epielpsy: a European double blind trial. Epilepsy Res 1993; 15: 6773.
  • 41
    Leppik IE, Willmore LJ, Homan RW. et al Efficacy and safety of znoisamide: results of a multicenter study. Epilepsy Res 1993; 14: 16573.
  • 42
    Browne TR, Leppik IE, Penry JK, Dean C, Buchanan RA. Zonisamide efficacy in long term studies. Epilepsia 1997; 38(suppl 8):108.
  • 43
    Kumagai N, Seki T, Yamawaki H. et al Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatr Neurol 1991; 45: 3579.
  • 44
    Seino M, Miyazaki H, Ito T. Zonisamide. In: PisaniF, PeruccaE, AvanziniG, RichensA eds. . New antiepileptic drugs. Epilepsy Res Suppl 3. New York : Elsevier, 1997: 16974.
  • 45
    Henry T, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1998; 38: 92831.
  • 46
    Kyllerman M, Ben-Menachem E. Long-term treatment of progressive myoclonic epilepsy syndromes with zonisamide and n-acetylcysteine [Abstract]. Epilepsia 1996; 37(suppl 5):172.
  • 47
    Yagi K, Seino M. Open clinical trial of new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures. Clin Psychiatry 1992; 29: 1119. (in Japanese).
  • 48
    Yamatogi Y, Ohtahara S. Current topics of treatment. In: OhtaharaS, RogerJ eds. . Proceedings of the international symposium, New Trends in Pediatric Epileptology. Okayama U Med School 1991; 13648.
  • 49
    Padgett CS, Bergen DC, French JA, Buchanan RA. Renal calculi associated with zonisamide [Abstract]. Epilepsia 37(suppl 5):173.
  • 50
    Berent S, Sackellares JC, Giordani B, Wagner JG, Donofrio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 617.
  • 51
    Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 1990; 31: 2147.
  • 52
    Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia 1994; 35: 4035.
  • 53
    Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37: 12424.
  • 54
    Naito H, Itoh N, Matsui N, Eguchi T. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 1988; 43: 4637.